Valuation: CellaVision AB

Market Cap 321.52Cr 33Cr 29Cr 27Cr 25Cr 47Cr 3.18TCr 48Cr 126.04Cr 1.56TCr 124.94Cr 122.24Cr 5.4TCr P/E 2026 *
23.8x
P/E 2027 * 19x
Enterprise Value 300.07Cr 31Cr 27Cr 25Cr 23Cr 44Cr 2.96TCr 45Cr 117.63Cr 1.46TCr 116.6Cr 114.08Cr 5.04TCr EV / Sales 2026 *
3.95x
EV / Sales 2027 * 3.49x
Free-Float
83.08%
Yield 2026 *
2.04%
Yield 2027 * 2.37%
1 day+3.78%
1 month+3.78%
3 months-13.23%
6 months-17.65%
Current year-16.80%
1 month 14
Extreme 14
14
Current year 13.49
Extreme 13.49
17.3
1 year 13.49
Extreme 13.49
17.3
3 years 13.49
Extreme 13.49
25.9
5 years 13.49
Extreme 13.49
34.75
10 years 13.49
Extreme 13.49
41.48
Manager TitleAgeSince
Chief Executive Officer - 05/06/2026
Director of Finance/CFO 46 02/09/2025
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 61 -
Director/Board Member 62 04/05/2018
Chairman 64 29/04/2021
Change 5-day change 1-year change 3-year change Capi.($)
+3.78%-.--% - - 33Cr
+4.33%+7.41%+7.70%-20.79% 1.67TCr
-0.17%-3.88%+12.54%+88.33% 161.76Cr
+0.40%-4.44%-44.76%-79.25% 118.93Cr
-1.54%-5.72%-32.17%+30.57% 109.09Cr
-1.25%-3.75%-30.70%-55.25% 61Cr
-0.99%-8.13%-41.22%-58.68% 53Cr
+0.09%+1.51%+27.76%-52.78% 45Cr
+1.22%-0.64%-55.74%-59.57% 38Cr
-0.92%-6.44%+14.99%+18.34% 31Cr
Average +0.50%-3.87%-15.73%-21.01% 253.83Cr
Weighted average by Cap. +3.07%-0.76%+0.70%-16.20%

Financials

2026 *2027 *
Net sales 76Cr 7.86Cr 6.87Cr 6.34Cr 5.86Cr 11Cr 749.8Cr 11Cr 30Cr 368.2Cr 29Cr 29Cr 1.28TCr 85Cr 8.79Cr 7.69Cr 7.09Cr 6.56Cr 12Cr 838.93Cr 13Cr 33Cr 411.97Cr 33Cr 32Cr 1.43TCr
Net income 14Cr 1.4Cr 1.22Cr 1.13Cr 1.04Cr 1.98Cr 133.54Cr 2.02Cr 5.3Cr 66Cr 5.25Cr 5.14Cr 227.14Cr 17Cr 1.79Cr 1.57Cr 1.45Cr 1.34Cr 2.54Cr 171.15Cr 2.58Cr 6.79Cr 84Cr 6.73Cr 6.59Cr 291.13Cr
Net Debt -21Cr -2.22Cr -1.94Cr -1.79Cr -1.66Cr -3.15Cr -211.9Cr -3.2Cr -8.41Cr -104.06Cr -8.33Cr -8.15Cr -360.44Cr -25Cr -2.6Cr -2.28Cr -2.1Cr -1.94Cr -3.69Cr -248.41Cr -3.75Cr -9.86Cr -121.99Cr -9.77Cr -9.56Cr -422.55Cr
Logo CellaVision AB
CellaVision AB is a Sweden-based company active in the medical technology sector. The Company develops and sells digital solutions for medical microscopy, as well as products enabling blood cell analysis and morphology diagnosis. CellaVision AB’s product portfolio consists of analyzers for automated medical microscopy analysis and software applications designed for remote access, competency testing and education. The analyzers include such brands as CellaVision DM96 and CellaVision DM1200, whereas the software applications are divided into CellaVision Body Fluid Application, CellaVision Remote Review Software and CellaVision Competency Software, among others. The Company operates four subsidiaries, based in Sweden, Canada, the United States and Japan. In June 2014, CellaVision AB acquired technology platform from Clear Lake Medical Foundation.
Employees
241
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
134.80SEK
Average target price
168.75SEK
Spread / Average Target
+25.19%

Quarterly revenue - Rate of surprise